Active substanceTrimetazidineTrimetazidine
Similar drugsTo uncover
  • Angiosyl® retard
    pills inwards 
  • Antisthene
    pills inwards 
    OZONE, LLC     Russia
  • Antisthene MB
    pills inwards 
    OZONE, LLC     Russia
  • Vero-Trimetazidine
    pills inwards 
    VEROPHARM SA     Russia
  • Deprenorm® MB
    pills inwards 
  • Deprenorm® MB
    pills inwards 
  • Predisin®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Preductal® MB
    pills inwards 
    SERVICE, CJSC     Russia
  • Preductal® OD
    capsules inwards 
    SERVICE, CJSC     Russia
  • Precard
    pills inwards 
  • Romekor
    pills inwards 
  • Romekor MB
    pills inwards 
  • Triducard®
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Trimectal® MB
    pills inwards 
    VERTEKS, AO     Russia
  • Tremet
    pills inwards 
  • Trimetaside
    pills inwards 
  • Trimetazidine
    pills inwards 
    ZIO-HEALTH, JSC     Russia
  • Trimetazidine
    pills inwards 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Trimetazidine
    pills inwards 
  • Trimetazidine
    pills inwards 
  • Trimetazidine
    pills inwards 
  • Trimetazidine
    capsules inwards 
    VERTEKS, AO     Russia
  • Trimetazidine
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Trimetazidine
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Trimetazidine MB
    pills inwards 
  • Trimetazidine MB
    pills inwards 
    ATOLL, LLC     Russia
  • Trimetazidine MB
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Trimetazidine MB
    pills inwards 
  • Trimetazidine MB-Teva
    pills inwards 
  • Trimetazidine-Biocom MB
    pills inwards 
    BIOKOM, CJSC     Russia
  • Trimetazidine-Teva
    pills inwards 
  • Trimittard MB
    pills inwards 
    ROMFARMA, OOO     Russia
  • Dosage form: & nbspExtended-release tablets coated with a film sheath
    Composition:

    1 tablet of prolonged action, film-coated, contains:

    active substance: trimetazidine dihydrochloride (in terms of 100% substance) - 35.0 mg;

    Excipients: mannitol - 13.5 mg, microcrystalline cellulose - 21.0 mg, mountain glycolic wax (wax monatin) - 39.0 mg, methyl methacrylate, trimethylammonioethyl methacrylate chloride and ethyl acrylate copolymer [1: 2: 0.1] (Eudragit Rs PO)-40.0 mg, magnesium stearate-1.5 mg;

    sheath - 8.0 mg: FD & C lacquer aluminum blue No. 2 - 0.07%, FD & C varnish aluminum, yellow № 6 - 0,77 %, macrogol (polyethylene glycol) - 20.20%, polyvinyl alcohol - 40.00%, lacquer aluminum Ponso 4R - 0.24%, talc-14.80%, titanium dioxide - 23.92 %.
    Description:Tablets of round shape, dao-convex, covered with a pink coating. On Two layers are visible in the cross section.
    Pharmacotherapeutic group:antihypoxic agent
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    C.01.E.B.15   Trimetazidine

    Pharmacodynamics:

    Has antihypoxic effect. Normalizes the energy metabolism of cells, exposed to hypoxia or ischemia. Directly influencing on cardiomyocytes and neurons of the brain, optimizes their metabolism and functionjune. Cytoprotective effect is due to an increase in the energy potential, activation of the oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and oxidation retardation fatty acids due to selective inhibition long-chain 3-ketoacyl-CoA thiolase).

    Trimetazidine supports contractility, myocardium, prevents a decrease intracellular content of adenosine triphosphate (ATP) and creatine phosphate.

    Under acidosis, it normalizes the functioning of ion channels of membranes, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular concentration of potassium ions.

    Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of ischemic damage to the myocardium.

    When angina pectoris reduces the frequency of attacks, reduces the need for nitrates, after 2 weeks of treatment increases exercise tolerance, sharp fluctuations in blood pressure decrease. Reduces dizziness and noise in the ears of ischemic etiology. In vascular pathology, the eye restores the functional activity of the retina.

    Pharmacokinetics:

    After oral administration trimetazidine quickly and almost completely absorbed in the gastrointestinal tract. Eating does not affect the pharmacokinetic properties of the drug. Bioavailability is 90%. The time to reach the maximum concentration in the blood plasma is 3-5 hours. During the day the concentration in the blood plasma remains at a level, exceeding 75% of the concentration, determined after 1 hour after taking one tablet of the drug. Equilibrium concentration in blood plasma is reached after about 60 h from treatment. The volume of distribution is 4.8 l / kg, communication with blood plasma proteins is 16%. Easily penetrates through the histohematological barriers. It is excreted unchanged, mainly by the kidneys (about 60%). Half-life is about 7 hours, in patients older than 65 years - about 12 hours. Renal clearance of trimetazidine directly correlates with creatinine clearance (CC), the liver clearance decreases with age.

    Indications:

    Cardiology: ischemic heart disease, prophylaxis of attacks of stable angina pectoris (as part of combination therapy).

    Otorhinolaryngology: treatment of cochlear-vestibular disorders of ischemic nature (such as dizziness, tinnitus, hearing impairment).

    Ophthalmology: chorioretinal vascular disorders with ischemic component.

    Contraindications:

    Hypersensitivity to the components of the drug, severe renal failure (creatinine clearance less than 15 ml / min), severe liver dysfunction, pregnancy, lactation, age under 18 (efficacy and safety not installed).

    Pregnancy and lactation:

    Studies on animals have not shown teratogenic effects of trimetazidine, however, due to the lack of clinical data on the safety of the drug during pregnancy, the risk of fetal malformations can not be ruled out.

    The use of the drug during pregnancy is contraindicated.

    It is not known whether trimetazidine with breast milk. If you need to use the drug Rimecor MB during lactation, it is necessary to interrupt breastfeeding.

    Dosing and Administration:

    Inside, during a meal.

    Римекор МВ apply on 1 tablet 2 times a day (in the morning and in the evening).

    If one admission is missed, the second dose should not double the dose of the drug. The course of treatment is recommended by a doctor

    Side effects:

    Frequency of side effects: very often (more than 1/10); often (more than 1/100 and less than 1/10); infrequently (more than 1/1000 and less than 1/100); rarely (more than 1/10000 and less than 1/1000); very rarely (more than 1 / 10,000), including individual messages.

    From the digestive system

    Often: abdominal pain, diarrhea, dyspepsia, nausea, vomiting;

    From the side of the cardiovascular system

    Rarely: orthostatic hypotension, "hot flashes" of blood to the skin of the face.

    From the central nervous system

    Often: dizziness, headache, asthenia.

    Very rarely: extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.

    From the skin

    Often: skin rash, itching, hives.

    Overdose:

    Data on overdose cases are limited. In case of an overdose, a symptomatic therapy.

    Interaction:There is no information.
    Special instructions:

    Rimecor MB is not intended for relief of angina attacks and is not indicated for the initial course of therapy for unstable angina or myocardial infarction, as well as in preparation for hospitalization or in its first days.

    In the case of an attack of angina pectoris, the treatment should be reviewed and adapted.

    Because of the lack of relevant clinical data, the use of Rimecor MB is not recommended for patients with renal insufficiency with creatinine clearance less than 15 ml / min, as well as for patients with severe impaired hepatic function.

    Effect on the ability to drive transp. cf. and fur:

    It is advisable to use caution when driving vehicles and engaging in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:Long-acting tablets, film-coated, 35 mg.
    Packaging:But 10 tablets in a contour melt packaging from polyvinylchloride film and aluminum foil.
    Three, six contour mesh packs of 10 tablets together with instructions for medical use the drug is placed in a pack of cardboard.
    Storage conditions:At a temperature of 15 ° C to 25 ° C.
    Keep out of the reach of children.
    Shelf life:3 years. Do not use after expiration. shelf life.
    Terms of leave from pharmacies:On prescription
    Registration number:PL-000826
    Date of registration:07.10.2011
    The owner of the registration certificate:Nizhny Novgorod Chemical and Pharmaceutical Plant, OJSCNizhny Novgorod Chemical and Pharmaceutical Plant, OJSC
    Manufacturer: & nbsp
    Information update date: & nbsp24.10.2015
    Illustrated instructions
      Instructions
      Up